Equities research analysts expect that Nevro Corp. (NYSE:NVRO) will announce $79.91 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Nevro Corp.’s earnings, with estimates ranging from $75.90 million to $83.73 million. Nevro Corp. posted sales of $60.92 million during the same quarter last year, which suggests a positive year-over-year growth rate of 31.2%. The business is scheduled to issue its next quarterly earnings results after the market closes on Monday, November 6th.

According to Zacks, analysts expect that Nevro Corp. will report full-year sales of $79.91 million for the current financial year, with estimates ranging from $314.01 million to $325.00 million. For the next fiscal year, analysts expect that the business will report sales of $406.33 million per share, with estimates ranging from $374.70 million to $428.39 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Nevro Corp..

Nevro Corp. (NYSE:NVRO) last issued its quarterly earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). The firm had revenue of $78.02 million for the quarter, compared to analysts’ expectations of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) earnings per share.

A number of research firms have commented on NVRO. Zacks Investment Research lowered shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Canaccord Genuity reiterated a “buy” rating and issued a $120.00 target price on shares of Nevro Corp. in a report on Sunday, October 8th. BidaskClub upgraded Nevro Corp. from a “sell” rating to a “hold” rating in a report on Saturday, October 7th. Northland Securities reiterated a “buy” rating and issued a $96.00 target price on shares of Nevro Corp. in a report on Tuesday, August 8th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $106.00 target price on shares of Nevro Corp. in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Nevro Corp. currently has a consensus rating of “Hold” and an average target price of $101.25.

Shares of Nevro Corp. (NYSE NVRO) opened at 87.58 on Wednesday. The stock’s 50 day moving average is $89.87 and its 200-day moving average is $83.58. The stock’s market capitalization is $2.58 billion. Nevro Corp. has a one year low of $65.82 and a one year high of $99.63.

COPYRIGHT VIOLATION WARNING: “Nevro Corp. (NVRO) Expected to Announce Quarterly Sales of $79.91 Million” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/01/nevro-corp-nvro-expected-to-announce-quarterly-sales-of-79-91-million.html.

In other news, CFO Andrew H. Galligan sold 7,000 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $82.31, for a total value of $576,170.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Wilfred E. Jaeger sold 79,657 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $82.74, for a total value of $6,590,820.18. The disclosure for this sale can be found here. Insiders sold a total of 290,907 shares of company stock worth $24,670,065 in the last quarter. 12.10% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Frontier Capital Management Co. LLC increased its holdings in Nevro Corp. by 497.4% in the third quarter. Frontier Capital Management Co. LLC now owns 761,770 shares of the medical equipment provider’s stock worth $69,230,000 after buying an additional 634,261 shares during the last quarter. Dupont Capital Management Corp increased its holdings in Nevro Corp. by 22.8% in the third quarter. Dupont Capital Management Corp now owns 9,029 shares of the medical equipment provider’s stock worth $821,000 after buying an additional 1,677 shares during the last quarter. Artemis Investment Management LLP acquired a new position in Nevro Corp. in the third quarter worth approximately $5,749,000. Hardman Johnston Global Advisors LLC increased its holdings in Nevro Corp. by 1.1% in the third quarter. Hardman Johnston Global Advisors LLC now owns 99,540 shares of the medical equipment provider’s stock worth $9,046,000 after buying an additional 1,050 shares during the last quarter. Finally, Fortaleza Asset Management Inc. increased its holdings in Nevro Corp. by 47.7% in the third quarter. Fortaleza Asset Management Inc. now owns 2,585 shares of the medical equipment provider’s stock worth $235,000 after buying an additional 835 shares during the last quarter.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Get a free copy of the Zacks research report on Nevro Corp. (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.